Report Description
Biosimilar Monoclonal Antibody Market Outlook
Biosimilar Monoclonal Antibody (mAbs) Market Report is expected to grow at CAGR 12.4% by 2025. Biosimilar Monoclonal Antibody (mAbs) Market Report was $107 Billion in 2020 and 114.56 in 2021 is expected to reach $180.2 Billion by the forecasted period 2021 to 2025. Growing geriatric population, increases in occurrence of diseases, such as rheumatoid arthritis and cancer, are the factors derive the growth of Biosimilar Monoclonal Antibody (mAbs) Market. In the product segment the Infliximab is covering the biggest segment around 40%. In the Application the biggest application is Autoimmune Disease shadowed by the Oncology. While the USA and China these are covering the market shares around 50% whereas the European region is sharing the biggest market share alone around 40%.What are Biosimilars?
Biologics are crucial parts within the treatment of patients with cancer. Biosimilars - biologics that are extremely just like approved biologics - supply a possible chance to extend access to biologics by stimulating price cutting war and should lower attention prices. The active substance of a biosimilar and also the original (approved medicine) are primarily constant biological substance, though' there could also be minor variations because of their complicated nature and also the production ways. A consequence of the astronomical business worth of mAbs related to the patent termination date (or calculable termination date) is their attractiveness as candidates for biosimilar medication. An acceptable definition of biosimilars includes the following: Biologic product with primary structure similar to the reference product that has been approved within the involved jurisdiction. Biosimilarity development pathway involving relevant orthogonal analytical comparison ways, and nonclinical and clinical models. Quality, nonclinical and clinical attributes are sufficiently similar, nevertheless not essentially identical between the biosimilar and also the reference product. Biosimilars are additional complicated than small-molecule medication and generics. Biological medicines (Biologics) are giant, complicated molecules made from living organisms that area unit usually tough to characterize and thus tough to repeat. Generic medicines (Generics) typically include little, identical molecules that are with chemicals synthesized. It?s necessary to know many key variations between biologics and small-molecule medication. Additionally, the producing method for biologics is additional complicated than for small-molecule medication, which needs multiple steps for cloning; choosing, maintaining, and increasing the cell line, and analytic, purifying, and characterizing the productDevelopment of antibody Biosimilars
Designed to be extremely just like originator biological products, biosimilars represent a chance to extend access and scale back prices for patients and attention systems. Biosimilars of monoclonal ought to demonstrate similar. Not all information of the originator product ought to be recapitulated, as giant numbers of patient-years of exposure information are already obtainable. A well-designed development program establishes biosimilarity supported structural, functional, presymptomatic, and clinical analysis. A scientific approach for characterization of structural and practical similarity of a biosimilar molecule to the mastermind molecule provides specifications to guide the event of biosimilars. Biosimilar endpoints area unit outlined for every tier of characterization, and analysis of serial tiers addresses extra connectedness of biosimilarity. Thus, biosimilar development is largely supported the security profiles of the originator product.Product Insights
Biosimilar Monoclonal Antibody (mAbs) Market report offers the market growth estimation, size and forecasts for every section, of the report the market trends and forecasts made in terms of revenue (USD million). Market segments is On the basis of Type (Synthetic Chemicals, Biopharmaceuticals, Others), On the basis of Application (Chronic & Autoimmune Diseases, Oncology, Others)Regional Insights
Biosimilar Monoclonal Antibody (mAbs) Market is segmented into regional presence. In the product segment the Infliximab is covering the biggest segment around 40%. In the Application the biggest application is Autoimmune Disease shadowed by the Oncology. While the USA and China these are covering the market shares around 50% whereas the European region is sharing the biggest market share alone around 40%. This report is covered into geographically, market share, revenue and growth of Biosimilar Monoclonal Antibody (mAbs) Market in these regions. North America (United States, Canada and Mexico), Latin America (Brazil, Argentina, Columbia etc.), Asia-Pacific (Australia, Indonesia, Thailand, Philippines, China, Japan, Korea, India, Asian country and Vietnam), Europe (Germany, UK, France, Italy, Russia and Turkey etc.), East and Africa (UAE, Egypt, Saudi peninsula, Nigeria and South Africa)Competitive Landscape
Biosimilar Monoclonal Antibody (mAbs) Market report includes company profiles that gives market outlook information, Business overview, business offerings, Key money Metrics (Total, Gross & Net), COVID-19 impact analysis, SWOT Analysis, Market Share, Production & capability (MW), Key Development Activities etc for market competitors are Allergan plc, Accord Healthcare Ltd, Alfred E. Tiefenbacher (GmbH & Co. KG), Biocon Limited, Boehringer Ingelheim GmbH, 3SBio, Inc., Novartis AG, Amgen, Inc., Alvartis Pharma, Pfizer, Inc., Celltrion, Hospira, and Dr. Reddy's Laboratories, and Others.Biosimilar Monoclonal Antibody (mAbs) Market Segments
On the basis of Type 1- Synthetic Chemicals 2- Biopharmaceuticals 3- Others On the basis of Application 1- Chronic & Autoimmune Diseases 2- Oncology 3- OthersTop Market Players covered in the Report
1- Allergan plc 2- Accord Healthcare Ltd 3- Alfred E. Tiefenbacher (GmbH & Co. KG) 4- Biocon Limited 5- Boehringer Ingelheim GmbH 6- 3SBio Inc 7- Novartis AG 8- Amgen Inc 9- Alvartis Pharma 10- Pfizer Inc 11- Celltrion 12- Hospira 13- Dr. Reddy's Laboratories 14- Others * Listed companies in this report may vary in the final report subject to Name Change / Merger etcGlobal Biosimilar Monoclonal Antibody Market: By Regional Analysis
1- North America A. U.S. B. Canada 2- Europe A. Germany B. U.K. C. France D. Italy E. Spain F. Rest of Europe 3- Asia Pacific A. China B. Japan C. India D. Rest of Asia Pacific 4- Latin America (LATAM) A. Brazil B. Mexico C. Rest of Latin America (LATAM) 5- Middle East & Africa (MEA) A. United Arab Emirates (UAE) B. Saudi Arabia C. Rest of Middle East & Africa (MEA) CSP Market Research analyst will gives you the thorough insightful information on Biosimilar Monoclonal Antibody Market Size, competitive landscape is delivered i.e. Revenue Share Analysis (MN USD) by top key Players, Revenue Market Share (%) by key Players and further a qualitative analysis is made headed for market cognizance rate, product differentiation, and new entrants are also considered in heat map concentration 1. Historical data- 2018 to 2019 2. The base year for estimation- 2020 3. Forecast period- 2021 to 2030Our Research Covers Competitors
1. Company Profile 2. Main Business Information 3. SWOT Analysis 4. Sales, Revenue, Price, and Gross Margin 5. Market ShareTarget Audience of the Biosimilar Monoclonal Antibody Market in this Study :
1. Key Consulting Companies & Advisors 2. Large, medium-sized, and small enterprises 3. Venture capitalists 4. Value-Added Resellers (VARs) 5. Third-party knowledge providers 6. Investment bankers 7. InvestorsKey Report Deliverables in the report Biosimilar Monoclonal Antibody Market
1- What is the market size and growth rate? 2- Inclusive details of factors that will challenge the growth of the market pre & post-COVID-19 with 4 types of market recovery scenarios including V shaped recovery, U shaped recovery, L shaped recovery, and W shaped recovery? 3- What are the factors anticipated to drive the global Biosimilar Monoclonal Antibody Market? 4- What are trends, restraints, and challenges in the global Biosimilar Monoclonal Antibody Market? 5- Segment-wise analysis of global Biosimilar Monoclonal Antibody Market? 6- Regional as well as country level analysis for Biosimilar Monoclonal Antibody Market? 7- Who are the potential customers of the global Biosimilar Monoclonal Antibody Market? 8- Analysis of major strategies by key market players? 9- How are collaborations evolving in the market? 10- How is the competitive environment? 11- Which region has attractive investment proposition? 12- Competitive Landscape with numerous analysis including revenue analysis, geographic presence analysis, competitive benchmarking, company evaluation matrix, competitive landscape, market positioning analysis, key strategies analysis, and others?Table of Content- Some Point Covered in the Report
Are you looking for a detailed TOC then speak with our analyst and fill the inquiry form. Chapter- 1. Research Framework keyword (Research Objective, Market Segmentation). Chapter- 2. Research Methodology- Qualitative Research, Primary & Secondary Sources, Quantitative Research, Primary & Secondary Sources, Market Size Estimation, Data Triangulation Chapter- 3. Executive Summary (Overview) Chapter- 4. Market Dynamics- Global Industry Outlook, Porter's Five Forces Model, COVID-19 Impact Assessment on Market, Major Strategies Adopted by Key Players, Market Positioning of Key Players Chapter- 5. Global keyword Analysis, by Market Segmentation- Key Insights, Market Size, and Forecast Chapter- 6. Global keyword Analysis, by Geography- Key Insights, Market Size, and Forecast (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). Chapter- 7. North America keyword Analysis- (Key Insights, Market Size, and Forecast, By Market Segmentation). Chapter- 8. Europe keyword Analysis- (Key Insights, Market Size, and Forecast, By Market Segmentation). Chapter- 9. Asia Pacific keyword Analysis- (Key Insights, Market Size, and Forecast, By Market Segmentation). Chapter- 10. Latin America keyword Analysis- (Key Insights, Market Size, and Forecast, By Market Segmentation). Chapter- 11. Middle East & Africa keyword Analysis- (Key Insights, Market Size, and Forecast, By Market Segmentation). Chapter- 12. Company Profiles- (Company, Company Basic Information, Manufacturing Base, Sales Area, Company Sales, and Net Income Highlights, Business Overview, Company News.Thanks for reading the article. We can also customize the report consistent with your requirements.
Geographical Analysis- Global Market Regional Analysis
What is the Report key Matric point?
Report Metric |
Details |
Market Study Available for Years |
2017–2030 Customize as per Requirement |
Base year Considered |
2020 Customize as per Requirement |
Historical Period |
2017- 2019 |
Forecast Period |
2021–2030 Customize as per Requirement |
Forecast Units |
Value (USD Million, Billion) As per Market |
Segments Covered |
Type, Application, and
Region- Customize as per Requirement |
Geographies Covered |
North America, Europe, Asia Pacific, Latin America, Middle East Africa and RoW- Customize as per Requirement |
Key Segments
Biosimilar Monoclonal Antibody (mAbs) Market Segments
On the basis of Type 1- Synthetic Chemicals 2- Biopharmaceuticals 3- Others On the basis of Application 1- Chronic & Autoimmune Diseases 2- Oncology 3- Others
Market Segments Covered in the Report (Additional can be Customized)
Table of Content
Table of Content- Biosimilar Monoclonal Antibody (mAbs) Market
1. Introduction 1.1. Objective of the Study 1.2. Market Definition 1.3. Scope of the Study 1.3.1. Market Segmentation 1.3.1.1. Biosimilar Monoclonal Antibody (mAbs) Market, By Type 1.3.1.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Application 1.3.1.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Geography 1.4. Currency Used 1.5. Years Considered for the Study 1.5.1. Historical Years 1.5.2. Base Year 1.5.3. Forecast Years 1.6. Limitations 1.7. Stakeholders 2. Executive Summary 2.1. Market Snapshot: Global Biosimilar Monoclonal Antibody (mAbs) Market 2.1.1. Interconnectivity and Related Markets 2.2. Key Insights 2.3. DROC (Drivers, Restraints, Opportunities, and Challenges) Analysis 2.4. Demand Side Trends 2.5. Supply Side Trends 2.6. Strategic Overview for Global Biosimilar Monoclonal Antibody (mAbs) Market 2.7. Voice of Industry Experts/Key Opinion Leaders (KOLs) 2.8. Recommendations and Conclusions 3. Research Methodology 3.1. Research Data 3.2. Market Breakdown and Data Triangulation 3.2.1. Secondary Research 3.2.2. Primary Research 3.2.3. Internal Repository Knowledge 3.3. Market Sizing Approach 3.3.1. 3600 View 3.3.2. Bottom Up Approach 3.3.3. Top Down Approach 3.4. Data Sources 3.4.1. Secondary Sources 3.4.2. Primary Sources 3.5. Name of Sources and References 4. COVID-19 Impact 4.1. COVID-19 Prevalence Analysis* 4.2. COVID-19 Vaccine Analysis* 4.3. COVID-19 Impact on Global Biosimilar Monoclonal Antibody (mAbs) Market 4.4. Pre vs Post COVID Demand and Supply Analysis 4.5. COVID-19 Road to Recovery Analysis 4.5.1. Global Biosimilar Monoclonal Antibody (mAbs) Market V Shaped Recovery 4.5.2. Global Biosimilar Monoclonal Antibody (mAbs) Market U Shaped Recovery 4.5.3. Global Biosimilar Monoclonal Antibody (mAbs) Market L Shaped Recovery 4.5.4. Global Biosimilar Monoclonal Antibody (mAbs) Market W Shaped Recovery 4.6. COVID-19 impact on End-user Industry 4.7. COVID-19 Opportunity Analysis 5. Prominent Insights 5.1. Macro-Economic Factors 5.1.1. Regional GDP Outlook 5.1.2. Key Industry News 5.1.3. Global Market Trend 5.1.3.1. Positive Trends 5.1.3.2. Negative Trends 5.1.4. Mechanism Integration 5.2. Ecosystem Mapping and Opportunity Analysis 5.3. Developed Vs Developing Economies 5.4. Market Dynamics 5.4.1. Market Drivers 5.4.1.1. Driver 1 5.4.1.2. Driver 2 5.4.1.3. Driver 3 5.4.1.4. Global Biosimilar Monoclonal Antibody (mAbs) Market Drivers Impact Assessment in the short, medium, and long terms 5.4.1.5. Global Biosimilar Monoclonal Antibody (mAbs) Market Drivers Impact Assessment at Regional Level 5.4.2. Market Restraints 5.4.2.1. Restraint 1 5.4.2.2. Restraint 2 5.4.2.3. Restraint 3 5.4.2.4. Global Biosimilar Monoclonal Antibody (mAbs) Market Restraints Impact Assessment in the short, medium, and long terms 5.4.2.5. Global Biosimilar Monoclonal Antibody (mAbs) Market Restraints Impact Assessment at Regional Level 5.4.3. Market Opportunities 5.4.3.1. Opportunity 1 5.4.3.2. Opportunity 2 5.4.3.3. Opportunity 3 5.4.3.4. Global Biosimilar Monoclonal Antibody (mAbs) Market Opportunities Impact Assessment in the short, medium, and long terms 5.4.3.5. Global Biosimilar Monoclonal Antibody (mAbs) Market Opportunities Impact Assessment at Regional Level 5.4.4. Market Challenges 5.4.4.1. Challenge 1 5.4.4.2. Challenge 2 5.4.4.3. Challenge 3 5.4.4.4. Global Biosimilar Monoclonal Antibody (mAbs) Market Challenges Impact Assessment in the short, medium, and long terms 5.4.4.5. Global Biosimilar Monoclonal Antibody (mAbs) Market Challenges Impact Assessment at Regional Level 5.5. Porter?s Five Forces Analysis 5.5.1. Threat Of New Entrants 5.5.2. Threat Of Substitutes 5.5.3. Bargaining Power Of Suppliers 5.5.4. Bargaining Power Of Buyers 5.5.5. Rivalry Among Existing Competitors 5.6. Value Chain Analysis 5.7. Attractive Investment Proposition, By Geography 5.8. Investment Landscape 5.8.1. Market Major Mergers & Acquisitions 5.8.2. Market Fund Raise and Other Activities 6. Global Biosimilar Monoclonal Antibody (mAbs) Market Analysis and Forecast, By Type, 2017-2028 (US$ Mn) 6.1. Overview 6.1.1. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Type, Market Share Comparison 2020 vs 2028 (%) 6.2. Synthetic Chemicals 6.2.1. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Synthetic Chemicals, Analysis and Forecast, 2017-2028 (US$ Mn) 6.2.2. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Synthetic Chemicals, Analysis and Forecast, By Region, 2017-2028 (US$ Mn) 6.3. Biopharmaceuticals 6.3.1. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Biopharmaceuticals, Analysis and Forecast, 2017-2028 (US$ Mn) 6.3.2. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Biopharmaceuticals, Analysis and Forecast, By Region, 2017-2028 (US$ Mn) 6.4. Others 6.4.1. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Others, Analysis and Forecast, 2017-2028 (US$ Mn) 6.4.2. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Others, Analysis and Forecast, By Region, 2017-2028 (US$ Mn) 7. Global Biosimilar Monoclonal Antibody (mAbs) Market Analysis and Forecast, By Application, 2017-2028 (US$ Mn) 7.1. Overview 7.1.1. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Application, Market Share Comparison 2020 vs 2028 (%) 7.2. Chronic & Autoimmune Diseases 7.2.1. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Chronic & Autoimmune Diseases, Analysis and Forecast, 2017-2028 (US$ Mn) 7.2.2. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Chronic & Autoimmune Diseases, Analysis and Forecast, By Region, 2017-2028 (US$ Mn) 7.3. Oncology 7.3.1. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Oncology, Analysis and Forecast, 2017-2028 (US$ Mn) 7.3.2. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Oncology, Analysis and Forecast, By Region, 2017-2028 (US$ Mn) 7.4. Others 7.4.1. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Others, Analysis and Forecast, 2017-2028 (US$ Mn) 7.4.2. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Others, Analysis and Forecast, By Region, 2017-2028 (US$ Mn) 8. Global Biosimilar Monoclonal Antibody (mAbs) Market Analysis and Forecast, By Regional Market Analysis, 2017-2028 (US$ Mn) 8.1. Overview 8.2. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Region, Market Share Comparison 2020 vs 2028 (%) 8.3. Global Biosimilar Monoclonal Antibody (mAbs) Market, By Region, Analysis and Forecast, 2017-2028 (US$ Mn) 8.4. Global Biosimilar Monoclonal Antibody (mAbs) Market, Regional Life Cycle Analysis 8.5. COVID-19 Impact on Global Biosimilar Monoclonal Antibody (mAbs) Market, By Region 9. North America Biosimilar Monoclonal Antibody (mAbs) Market Analysis and Forecast, By Regional Market Analysis, 2017-2028 (US$ Mn) 9.1. North America Biosimilar Monoclonal Antibody (mAbs) Market Overview 9.2. North America Biosimilar Monoclonal Antibody (mAbs) Market Summary 9.2.1. Dynamics 9.2.2. Impact Analysis 9.3. North America Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 9.4. North America Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 9.5. North America Biosimilar Monoclonal Antibody (mAbs) Market, By Country, 2017-2028 (US$ Mn) 9.5.1. U.S. 9.5.1.1. Overview 9.5.1.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 9.5.1.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 9.5.2. Canada 9.5.2.1. Overview 9.5.2.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 9.5.2.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 10. Europe Biosimilar Monoclonal Antibody (mAbs) Market Analysis and Forecast, By Regional Market Analysis, 2017-2028 (US$ Mn) 10.1. Europe Biosimilar Monoclonal Antibody (mAbs) Market Overview 10.2. Europe Biosimilar Monoclonal Antibody (mAbs) Market Summary 10.2.1. Dynamics 10.2.2. Impact Analysis 10.3. Europe Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 10.4. Europe Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 10.5. Europe Biosimilar Monoclonal Antibody (mAbs) Market, By Country, 2017-2028 (US$ Mn) 10.5.1. Germany 10.5.1.1. Overview 10.5.1.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 10.5.1.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 10.5.2. U.K. 10.5.2.1. Overview 10.5.2.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 10.5.2.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 10.5.3. France 10.5.3.1. Overview 10.5.3.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 10.5.3.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 10.5.4. Italy 10.5.4.1. Overview 10.5.4.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 10.5.4.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 10.5.5. Spain 10.5.5.1. Overview 10.5.5.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 10.5.5.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 10.5.6. Rest of Europe 10.5.6.1. Overview 10.5.6.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 10.5.6.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 11. Asia Pacific Biosimilar Monoclonal Antibody (mAbs) Market Analysis and Forecast, By Regional Market Analysis, 2017-2028 (US$ Mn) 11.1. Asia Pacific Biosimilar Monoclonal Antibody (mAbs) Market Overview 11.2. Asia Pacific Biosimilar Monoclonal Antibody (mAbs) Market Summary 11.2.1. Dynamics 11.2.2. Impact Analysis 11.3. Asia Pacific Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 11.4. Asia Pacific Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 11.5. Asia Pacific Biosimilar Monoclonal Antibody (mAbs) Market, By Country, 2017-2028 (US$ Mn) 11.5.1. China 11.5.1.1. Overview 11.5.1.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 11.5.1.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 11.5.2. Japan 11.5.2.1. Overview 11.5.2.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 11.5.2.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 11.5.3. India 11.5.3.1. Overview 11.5.3.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 11.5.3.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 11.5.4. Rest of Asia Pacific 11.5.4.1. Overview 11.5.4.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 11.5.4.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 12. Latin America (LATAM) Biosimilar Monoclonal Antibody (mAbs) Market Analysis and Forecast, By Regional Market Analysis, 2017-2028 (US$ Mn) 12.1. Latin America (LATAM) Biosimilar Monoclonal Antibody (mAbs) Market Overview 12.2. Latin America (LATAM) Biosimilar Monoclonal Antibody (mAbs) Market Summary 12.2.1. Dynamics 12.2.2. Impact Analysis 12.3. Latin America Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 12.4. Latin America Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 12.5. Latin America (LATAM) Biosimilar Monoclonal Antibody (mAbs) Market, By Country, 2017-2028 (US$ Mn) 12.5.1. Brazil 12.5.1.1. Overview 12.5.1.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 12.5.1.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 12.5.2. Mexico 12.5.2.1. Overview 12.5.2.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 12.5.2.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 12.5.3. Rest of Latin America (LATAM) 12.5.3.1. Overview 12.5.3.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 12.5.3.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 13. Middle East & Africa (MEA) Biosimilar Monoclonal Antibody (mAbs) Market Analysis and Forecast, By Regional Market Analysis, 2017-2028 (US$ Mn) 13.1. Middle East & Africa (MEA) Biosimilar Monoclonal Antibody (mAbs) Market Overview 13.2. Middle East & Africa (MEA) Biosimilar Monoclonal Antibody (mAbs) Market Summary 13.2.1. Dynamics 13.2.2. Impact Analysis 13.3. Middle East and Africa Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 13.4. Middle East and Africa Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 13.5. Middle East & Africa (MEA) Biosimilar Monoclonal Antibody (mAbs) Market, By Country, 2017-2028 (US$ Mn) 13.5.1. United Arab Emirates (UAE) 13.5.1.1. Overview 13.5.1.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 13.5.1.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 13.5.2. Saudi Arabia 13.5.2.1. Overview 13.5.2.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 13.5.2.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 13.5.3. Rest of Middle East & Africa (MEA) 13.5.3.1. Overview 13.5.3.2. Biosimilar Monoclonal Antibody (mAbs) Market, By Type, 2017-2028 (US$ Mn) 13.5.3.3. Biosimilar Monoclonal Antibody (mAbs) Market, By Application, 2017-2028 (US$ Mn) 14. Competitive Landscape 14.1. Key Players Overview 14.2. Products/Service Comparison of Key Players 14.3. Geographic Presence Analysis of Key Players 14.4. Competitive Benchmarking 14.5. Company Evaluation Matrix 14.5.1. Star 14.5.2. Emerging Leader 14.5.3. Pervasive 14.5.4. Participant 14.6. Competitive Landscape 14.6.1. Small Players 14.6.2. Medium Players 14.6.3. Large Players 14.7. Market Positioning of Key Players 14.8. Investment Scenario of Key Players 14.9. Strategies Analysis of Key Players 14.9.1. Mergers & Acquisitions 14.9.2. Joint Ventures 14.9.3. New Product Development 14.9.4. Joint Ventures 14.9.5. Partnerships 14.9.6. Others 15. Company Profiles (Business Overview, Products/ Solutions Offered, Recent Developments, Strategic Initiatives, Financial Summary, etc.) 15.1. Allergan plc 15.1.1. Company and Business Overview 15.1.2. Products and Service Offerings 15.1.3. Business Presence, Key Personnel, Company Contact Details, and Competitors 15.1.4. Strategic Initiatives 15.1.5. Key Financial Summary* 15.1.5.1. Recent Financials (2016-2020) 15.1.5.2. Business Revenue, 2020 (in %) 15.1.5.3. Geographic Revenue, 2020 (in %) 15.2. Accord Healthcare Ltd 15.3. Alfred E. Tiefenbacher (GmbH & Co. KG) 15.4. Biocon Limited 15.5. Boehringer Ingelheim GmbH 15.6. 3SBio Inc 15.7. Novartis AG 15.8. Amgen Inc 15.9. Alvartis Pharma 15.10. Pfizer Inc 15.11. Celltrion 15.12. Hospira 15.13. Dr. Reddy's Laboratories 15.14. Others *Financial details might not be captured in case of privately-held companies or for companies that do not report this information in public domain
Key Players
Top Market Players covered in the Report
1- Allergan plc 2- Accord Healthcare Ltd 3- Alfred E. Tiefenbacher (GmbH & Co. KG) 4- Biocon Limited 5- Boehringer Ingelheim GmbH 6- 3SBio Inc 7- Novartis AG 8- Amgen Inc 9- Alvartis Pharma 10- Pfizer Inc 11- Celltrion 12- Hospira 13- Dr. Reddy's Laboratories 14- Others * Listed companies in this report may vary in the final report subject to Name Change / Merger etc